Wrapmanager Inc. lessened its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 8.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,759 shares of the medical equipment provider’s stock after selling 1,823 shares during the period. Wrapmanager Inc. owned about 0.05% of Lantheus worth $587,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in LNTH. Mason Street Advisors LLC boosted its position in shares of Lantheus by 3.6% during the 1st quarter. Mason Street Advisors LLC now owns 12,380 shares of the medical equipment provider’s stock worth $303,000 after acquiring an additional 435 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Lantheus by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 26,714 shares of the medical equipment provider’s stock valued at $418,000 after acquiring an additional 587 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Lantheus by 0.9% during the fourth quarter. Legal & General Group Plc now owns 82,403 shares of the medical equipment provider’s stock valued at $1,272,000 after acquiring an additional 721 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Lantheus by 1.3% during the second quarter. Arizona State Retirement System now owns 60,218 shares of the medical equipment provider’s stock valued at $1,704,000 after acquiring an additional 752 shares during the last quarter. Finally, Texas Permanent School Fund raised its stake in shares of Lantheus by 4.0% during the first quarter. Texas Permanent School Fund now owns 26,173 shares of the medical equipment provider’s stock valued at $641,000 after acquiring an additional 1,002 shares during the last quarter. Hedge funds and other institutional investors own 91.35% of the company’s stock.
In other Lantheus news, COO John J. Bolla sold 1,747 shares of Lantheus stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $27.56, for a total value of $48,147.32. Following the sale, the chief operating officer now owns 37,155 shares of the company’s stock, valued at $1,023,991.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Derace L. Schaffer sold 20,000 shares of Lantheus stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $23.82, for a total transaction of $476,400.00. Following the completion of the sale, the director now directly owns 36,994 shares in the company, valued at approximately $881,197.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,187 shares of company stock worth $3,604,063. Insiders own 2.60% of the company’s stock.
Lantheus stock traded down $0.58 during midday trading on Wednesday, hitting $21.88. 3,207 shares of the stock were exchanged, compared to its average volume of 366,399. Lantheus Holdings Inc has a 52-week low of $12.59 and a 52-week high of $29.80. The company has a market capitalization of $881.99 million, a PE ratio of 23.26, a price-to-earnings-growth ratio of 1.79 and a beta of 1.47. The stock’s 50-day simple moving average is $25.97. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share for the quarter, hitting the consensus estimate of $0.27. The business had revenue of $85.70 million for the quarter, compared to analysts’ expectations of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.25 earnings per share. As a group, analysts predict that Lantheus Holdings Inc will post 1.06 EPS for the current year.
LNTH has been the subject of a number of analyst reports. BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 11th. Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Friday, August 2nd. Finally, ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Further Reading: Bid-Ask Spread
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.